Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members.
She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees.
Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.
J&J plans to separate its pharma and medical devices businesses into one company and its consumer health business into another company. What’s behind the new J&J?
Lengthy early-development timelines are common across new and emerging biotech companies for a multitude of reasons. Striking the right balance of speed, quality, risk, and investment allows you to shorten…
Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. Key topics: (see Chapter Markers in drop down…
The Latest in the Battle for US Drug-Pricing Reform
Drug-pricing reform in the US is on the table once again as Congress and the Biden Administration seek to move forward with a new plan. What’s in the plan?
Novartis is starting a strategic review of Sandoz, its generics and biosimilars business. Is another wave of industry consolidation in the generics industry on tap?
The FDA has approved 42 new molecular entities thus far in 2021. Which products launched or expected to be launched in 2021 have blockbuster potential?
FDA Issues Draft Guidance on Continuous Manufacturing
The FDA has issued draft guidance for continuous manufacturing of drug substances and drug products. Industry feedback is due by mid-December. What does the FDA say?
Manufacturing 4.0: A Look at the Bio/Pharma Industry
Manufacturing 4.0 is used to denote “smart factories” with increased levels of digitalization and automation. Where does the bio/pharma industry stand?
